United States Hereditary Angioedema Therapeutics Market Report and Forecast 2024-2032

United States Hereditary Angioedema Therapeutics Market Size

The United States hereditary angioedema therapeutics market is expected to grow at a CAGR of 8.20% during the forecast period of 2024-2032, driven by the rising development of novel therapies, the favorable regulatory environment, and the growing patient awareness regarding hereditary angioedema diagnosis and treatment options in the region.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

United States Hereditary Angioedema Therapeutics Market Outlook

• Increased awareness among the public and healthcare providers and the rising diagnosis rates drives the demand for effective therapeutics for hereditary angioedema.

• One of the major market trends is the rising patient inclination towards prophylactic treatments due to their ability to prevent HAE attacks before they occur, thus improving the patient's quality of life.

• Surge in regulatory approvals and expanding pipelines for hereditary angioedema therapies are some of the factors fuelling the market growth in the United States.

United States Hereditary Angioedema Therapeutics Market Overview

Hereditary angioedema (HAE) is a hereditary disorder in which the patient suffers from recurring attacks of severe swelling in body parts including hands, face, feet, and intestinal walls. It is caused by the deficiency or improper functioning of a protein that is a C1 inhibitor and can be life-threatening. There are numerous medications and therapies available to treat the condition and help control or prevent the swelling from occurring. In the United States, cases of hereditary angioedema are on the rise, which is fueling the United States hereditary angioedema therapeutics market demand.

Hereditary angioedema therapies have been progressing with time and now effective medications are available such as Garadacimab. Key players are continuously striving to innovate and develop better treatment options which also impacts the dynamics of the global hereditary angioedema therapeutics market . Patients depending on the therapies are receiving positive results which is ultimately resulting in the growth of the market. Unawareness about the disease can lead to misdiagnosis, and delay treatment. Organizations such as the United States Hereditary Angioedema Association are spreading awareness about the condition, its causes, and the treatments available, further supporting the expansion of the United States hereditary angioedema therapeutics market.

Home-based treatments are available for hereditary angioedema which have aided in reducing the seriousness of attacks and improving the quality of life of the patient. Factors such as the rising development of long-acting prophylactic therapies, increased regulatory approvals, and expanding pipelines for hereditary angioedema therapies are expected to bolster the market share in the forecast period.

United States Hereditary Angioedema Therapeutics Market Growth Drivers

Surge in FDA Approval of Hereditary Angioedema Drugs to Fuel the Market Demand

The surge in regulatory approvals of new therapies indicated for hereditary angioedema by the United States Food and Drug Administration (FDA) is projected to propel the market growth. For instance, in February 2023, Takeda Pharmaceuticals announced that its human monoclonal antibody TAKHZYRO® (lanadelumab-flyo) received clearance from the FDA for preventing hereditary angioedema (HAE) attacks in children aged 2 to 6 years, making it the first and only approved HAE prophylaxis treatment in this age category in the United States.

Moreover, in August 2023, the FDA also granted approval to Eugia Pharma Specialities Limited's (subsidiary of Aurobindo Pharma) generic version of Firazyr (icatibant injection) indicated for treating acute swelling attacks of hereditary angioedema in adults. The rising introduction of such therapies for HAE is likely to expand the range of available treatment options in the United States and boost the market growth.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

United States Hereditary Angioedema Therapeutics Market Trends

The market is witnessing several trends and developments to improve the current scenario in the United States. Some of the notable trends are as follows:

United States Hereditary Angioedema Therapeutics Market Segmentation

Market Breakup by Drug Type

• C1-Esterase Inhibitor

• Bradykinin B2 Receptor Antagonist

• Kallikrein Inhibitor

• Others

Market Breakup by Route of Administration

• Parenteral

• Oral

United States Hereditary Angioedema Therapeutics Market Share

Market Segmentation Based on Drug Type is Poised to Witness Substantial Growth

Based on the drug type, the market is segmented into C1-esterase inhibitors, bradykinin B2 receptor antagonists, and kallikrein inhibitors, among others. In children aged 12 years and above, hereditary angioedema is treated through drugs such as Kallikrin inhibitors, while in adults, C1 esterase inhibitors and B2 bradykinin receptor antagonists are used. C1 esterase inhibitors, which also act as an anti-inflammatory agent, have been leading the United States hereditary angioedema therapeutics market because it has the potential to treat other diseases along with hereditary angioedema.

Parenteral and Oral Routes Expected to Lead the Market Share

The market segmentation on the basis of route of administration includes parenteral and oral. The route of administration of medicine varies depending on the condition of the patient and the frequency of medication administration. The parenteral segment occupies a significant segment of the market as many therapies require urgent administration and faster impact. A parenteral route such as intravenous therapy is useful for patients already fitted with IV drips, while subcutaneous therapy can be effective for individuals who need quick administration. Long-term medication is most administered through oral forms to reduce the effect of the disorder.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

United States Hereditary Angioedema Therapeutics Market Analysis by Region

The key regions of the United States market for hereditary angioedema therapeutics include the Northeast region, Southeast region, Midwest region, Southwest region, and West region. The Northeast region represents a considerable market share owing to the presence of leading pharmaceutical companies and biotechnology firms as well as the establishment of various specialized healthcare centers and clinics that focus on treating rare genetic disorders like hereditary angioedema. Other regions such as the Southeast and Midwest are also experiencing significant market growth driven by expanding healthcare facilities and increasing investment in biomedical research and innovation.

Leading Players in the United States Hereditary Angioedema Therapeutics Market

The key features of the market report include clinical trial analysis, grants analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited, founded in 1781, has its headquarters in Tokyo, Japan. It is a global pharmaceutical company that carries out research and innovates in medicine for the better health of patients worldwide. One of its key products is TAKHZYRO® (lanadelumab-flyo) which is a monoclonal antibody that helps in preventing hereditary angioedema attacks.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. was established in 1986 with headquarters in North Carolina, United States. It is an American biotech company that deals with medicines, particularly oral drugs, that are prescribed for rare diseases. BioCryst is known for developing ORLADEYO® (berotralstat), the first oral, once-daily therapy for the prevention of HAE attacks and plays a significant role in the United States hereditary angioedema therapeutics market growth.

Sanofi

Sanofi S.A. founded in 2004 has its headquarters located in Paris, France. It is a healthcare company that manufactures vaccines and medicines for rare blood disorders, cardiovascular diseases, diabetes, and various other serious diseases. The company is actively engaged in R&D initiatives aimed at developing advanced therapies for hereditary angioedema.

CSL Behring LLC

The pioneering biotechnology company CSL Behring LLC. specializes in plasma-derived and recombinant therapies for rare diseases and is headquartered in Pennsylvania, USA. One of its leading assets for hereditary angioedema is Garadacimab, which received acceptance of its Biologics License Application (BLA) from the FDA in December 2023.

Other key players in the market include Pharming Group N.V., Cipla Inc., Ionis Pharmaceuticals Inc., Attune Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Arrowhead Pharmaceuticals, Inc., and Pharvaris B.V.

Key Highlights of the Report

Key Questions Answered in the United States Hereditary Angioedema Therapeutics Market Report 

• What was the United States hereditary angioedema therapeutics market value in 2023?
• What is the United States hereditary angioedema therapeutics market forecast outlook for 2024-2032?
• What is market segmentation based on drug type?
• What is the market breakup based on the route of administration?
• What are the major factors aiding the United States hereditary angioedema therapeutics market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• How does the prevalence and incidence of hereditary angioedema in the United States affect the market landscape?
• What are the major United States hereditary angioedema therapeutics market trends?
• How do the rising advancements in therapeutic options impact the market size?
• Which drug type will dominate the market share? 
• Which route of administration is expected to have a high market value in the coming years?
• Who are the key players involved in the United States hereditary angioedema therapeutics market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, and mergers & acquisitions among the key market players shaping the market dynamics?